721,700 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Acquired by Zimmer Partners LP

Key Points

• Zimmer Partners LP has acquired a new stake in Teva Pharmaceutical Industries, purchasing 721,700 shares valued at approximately $11.09 million, giving them about 0.06% ownership in the company as of the last quarter.
• Shares of Teva Pharmaceutical Industries are currently trading at around $19.30 with a market capitalization of $22.13 billion, showcasing a 52-week range of $12.47 to $22.80.
• Analysts have upgraded Teva’s stock ratings, with several firms setting target prices ranging from $23.00 to $25.00, indicating a consensus rating of "Buy" with a target of $24.71.

Zimmer Partners LP purchased a new position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 721,700 shares of the company's stock, valued at approximately $11,093,000. Zimmer Partners LP owned about 0.06% of Teva Pharmaceutical Industries as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in TEVA. Golden State Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries in the first quarter worth $39,000. New Age Alpha Advisors LLC bought a new stake in Teva Pharmaceutical Industries in the first quarter worth $43,000. Compagnie Lombard Odier SCmA bought a new stake in Teva Pharmaceutical Industries in the first quarter worth $54,000. Banque Cantonale Vaudoise bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at about $74,000. Finally, Brooklyn Investment Group raised its stake in shares of Teva Pharmaceutical Industries by 403.4% during the first quarter. Brooklyn Investment Group now owns 5,009 shares of the company's stock valued at $77,000 after acquiring an additional 4,014 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider owned 6,774 shares in the company, valued at approximately $102,693.84. This represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Eric A. Hughes sold 52,742 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Trading Up 0.4%

Shares of NYSE TEVA traded up $0.07 during midday trading on Friday, hitting $19.96. 9,141,743 shares of the company traded hands, compared to its average volume of 9,876,074. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The stock has a 50-day moving average price of $17.31 and a 200 day moving average price of $16.50. The firm has a market cap of $22.89 billion, a P/E ratio of -124.75, a P/E/G ratio of 1.16 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's revenue was up .3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective for the company. The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 price objective for the company. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $24.71.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.